Dataset Open Access

Analysis of Huntingtin BioID Datasets 2019/04/09

Harding, Rachel; Hesketh, Geoff; Arrowsmith, Cheryl; Edwards, Aled


Citation Style Language JSON Export

{
  "publisher": "Zenodo", 
  "DOI": "10.5281/zenodo.3234159", 
  "title": "Analysis of Huntingtin BioID Datasets 2019/04/09", 
  "issued": {
    "date-parts": [
      [
        2019, 
        4, 
        9
      ]
    ]
  }, 
  "abstract": "<p><strong>Project:&nbsp;</strong>Investigation of putative HTT interacting proteins</p>\n\n<p><strong>Experiment:&nbsp;</strong>Analysis of HTT BioID datasets&nbsp;</p>\n\n<p><strong>Date completed:&shy;&nbsp;</strong>2019/04/09</p>\n\n<p><strong>Rationale:&nbsp;</strong>BioID technology employs a promiscuous biotin ligase (BirA) fused to the terminus of the target protein, huntingtin, allowing proximal proteins to be biotinylated and then subsequently identified through mass spectrometry experiments. This technique has not been applied to assess huntingtin interactors to date in the published literature, so will provide a novel methodology to characterize the huntingtin interactome. As huntingtin is a large protein molecule and the precise location of the N and C-termini remain unresolved due to their flexible nature, both N and C terminally BirA-tagged constructs for full-length huntingtin will be generated for overexpression as well as a truncated construct spanning amino acids 80-3100, the region of the protein resolved in the recent cryo-electron microscopy structure which omits the flexible termini. Huntingtin fusion proteins will be overexpressed in cells subjected to different ROS stresses as well as control conditions. Resultant cell lysates will be analysed through collaboration with Prof. Anne-Claude Gingras (Lunenfeld Tanenbaum Research Institute, University of Toronto). From this work, we hope to obtain a list of putative huntingtin interactors which will be compared to previously published findings and assessed for stable complex formation with huntingtin</p>", 
  "author": [
    {
      "family": "Harding, Rachel"
    }, 
    {
      "family": "Hesketh, Geoff"
    }, 
    {
      "family": "Arrowsmith, Cheryl"
    }, 
    {
      "family": "Edwards, Aled"
    }
  ], 
  "note": "Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, S\u00e3o Paulo Research Foundation-FAPESP, Takeda, and Wellcome.", 
  "type": "dataset", 
  "id": "3234159"
}
101
75
views
downloads
All versions This version
Views 10186
Downloads 7558
Data volume 40.7 MB37.4 MB
Unique views 7270
Unique downloads 4140

Share

Cite as